Literature DB >> 20351624

Protective effect of high-mobility group box 1 blockade on acute liver failure in rats.

Kiminori Takano1, Masahiro Shinoda, Minoru Tanabe, Taku Miyasho, Shingo Yamada, Shigeshi Ono, Yohei Masugi, Koichi Suda, Koichi Fukunaga, Tetsu Hayashida, Taizo Hibi, Hideaki Obara, Hiroya Takeuchi, Shigeyuki Kawachi, Kazufumi Kawasako, Minoru Okamoto, Hiroshi Yokota, Ikuro Maruyama, Yuko Kitagawa.   

Abstract

High-mobility group box 1 (HMGB1) is a monocyte-derived inflammatory mediator that is released in some conditions including shock, tissue injury, and endotoxin-induced lethality. In this study, we determined the plasma and hepatic tissue levels of HMGB1 in a drug-induced rat acute liver failure (ALF) model and investigated the effect of HMGB1 blockade on ALF. Adult male Sprague-Dawley rats, weighing 250 to 300 g, were used for this study. d-galactosamine was injected into the penile vein to induce ALF. To determine HMGB1 levels, plasma and hepatic tissue samples were serially collected after the d-galactosamine injection. To test the effect of HMGB1 blockade, anti-HMGB1 polyclonal antibodies or control antibodies were injected into the penile vein right after injection of d-galactosamine. Levels of HMGB1 were increased in plasma and decreased in hepatic tissue after induction of ALF. Immunohistochemical examination for HMGB1 showed that liver from animals with ALF had little staining, whereas normal liver had strong staining in the nuclei. Injection of anti-HMGB1 antibodies resulted in significant suppression of plasma HMGB1 and hepatic enzymes, marked suppression of plasma inflammatory cytokines, marked improvement of histological findings, and significant improvement of survival. The decrease of hepatic HMGB1 was also significantly suppressed in the group injected with anti-HMGB1 antibodies. The present study suggests that in ALF, the liver may release HMGB1 into the plasma, and that neutralizing the released HMGB1 has a protective effect against injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351624     DOI: 10.1097/SHK.0b013e3181df0433

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  13 in total

1.  Farnesyltransferase inhibitor, tipifarnib, prevents galactosamine/lipopolysaccharide-induced acute liver failure.

Authors:  Masao Kaneki; Fumito Ichinose; Kazuhiro Shirozu; Shuichi Hirai; Tomokazu Tanaka; Shinsuke Hisaka
Journal:  Shock       Date:  2014-12       Impact factor: 3.454

2.  Endotoxin tolerance alleviates experimental acute liver failure via inhibition of high mobility group box 1.

Authors:  Nai-Bin Yang; Shun-Lan Ni; Shan-Shan Li; Sai-Nan Zhang; Dan-Ping Hu; Ming-Qin Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development.

Authors:  Kiyoshi Kikuchi; Hisaaki Uchikado; Naoki Miura; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Kei Miyata; Rokudai Sakamoto; Chiemi Kikuchi; Narumi Iida; Naoto Shiomi; Terukazu Kuramoto; Naohisa Miyagi; Ko-Ichi Kawahara
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

Review 4.  Targeting HMGB1 in the treatment of sepsis.

Authors:  Haichao Wang; Mary F Ward; Andrew E Sama
Journal:  Expert Opin Ther Targets       Date:  2014-01-06       Impact factor: 6.902

5.  HMGB1 cytoplasmic translocation in patients with acute liver failure.

Authors:  Rong-Rong Zhou; Shu-Shan Zhao; Ming-Xiang Zou; Pan Zhang; Bao-Xing Zhang; Xia-Hong Dai; Ning Li; Hong-Bo Liu; Haichao Wang; Xue-Gong Fan
Journal:  BMC Gastroenterol       Date:  2011-03-15       Impact factor: 3.067

6.  Quercetin Protects Mice from ConA-Induced Hepatitis by Inhibiting HMGB1-TLR Expression and Down-Regulating the Nuclear Factor Kappa B Pathway.

Authors:  Xi Li; Hong-Chun Liu; Qun-Yan Yao; Bei-Li Xu; Shun-Cai Zhang; Chuan-Tao Tu
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

7.  Curcumin protects against concanavalin A-induced hepatitis in mice through inhibiting the cytoplasmic translocation and expression of high mobility group box 1.

Authors:  Chuan-tao Tu; Qun-yan Yao; Bei-li Xu; Shun-cai Zhang
Journal:  Inflammation       Date:  2013-02       Impact factor: 4.092

Review 8.  The sterile inflammation in the exacerbation of HBV-associated liver injury.

Authors:  Qiao Yang; Yu Shi; Ying Yang; Guohua Lou; Zhi Chen
Journal:  Mediators Inflamm       Date:  2015-03-29       Impact factor: 4.711

Review 9.  Potential of the angiotensin receptor blockers (ARBs) telmisartan, irbesartan, and candesartan for inhibiting the HMGB1/RAGE axis in prevention and acute treatment of stroke.

Authors:  Kiyoshi Kikuchi; Salunya Tancharoen; Takashi Ito; Yoko Morimoto-Yamashita; Naoki Miura; Ko-ichi Kawahara; Ikuro Maruyama; Yoshinaka Murai; Eiichiro Tanaka
Journal:  Int J Mol Sci       Date:  2013-09-13       Impact factor: 5.923

Review 10.  High-Mobility Group Box-1 and Liver Disease.

Authors:  Harriet Gaskell; Xiaodong Ge; Natalia Nieto
Journal:  Hepatol Commun       Date:  2018-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.